- Description
Product name: Atosiban Acetate
Molecular Formula: C43H67N11O12S2
Molecular Weight: 994.2
CAS No.: 90779-69-4
Quality standard: enterprise standard, 98% up by HPLC
Sequence: c[Mpa-D-Tyr(Et)-Ile-Thr-Asn-Cys]-Pro-Orn-Gly-NH2
Appearance: White powder
Specific Optical Rotation (c=1,1%HAc): -45.0~-55.0°
Water Content(Karl Fischer): ≤5.0%
Acetate Content(by HPLC): ≤15.0% Amino Acid Composition :±10% of theoretical
Purity(by HPLC): ≥98.0%
Single Impurity(by HPLC): ≤1.0%
Peptide Content(by %N): ≥80%
Assay(By Anhydrous, Acetic Acid-free ): 95.0~105.0%
Bacterial Endotoxins: ≤5EU/mg
Density: 1.254 g/cm3
Bioling Point: 1469ºC at 760 mmHg
Flash Point: 842.2ºC
Refraction Optical Ratio: 1.549
Usage: Atosiban is an oxytocin receptor blocking agent in the treatment of experimental endometriosis and was shown exhibit significant therapeutic efficiency.
Storage: Keep in a cool(2~8 °C) & dry place protected from light, keep package close when not in use.
Description:
Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985.[1] Originally marketed by Ferring Pharmaceuticals, it is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women.